When 4-year-old Mateo Rivera got his new heart valve, doctors didn’t just fix a leak—they gave him room to grow. Unlike traditional valves that wear out or become too small as kids develop, Mateo’s implant, the Autus Size-Adjustable Valve, can stretch from 13 millimeters to nearly adult size without another open-heart surgery.
For years, children born with serious heart defects faced a cruel trade-off: get a replacement valve early and risk needing repeated surgeries, or wait and risk permanent heart damage. Congenital heart defects affect about 1 in 100 U.S. babies, and around 4,200 of them each year have pulmonary valve conditions so severe they eventually need a new valve. Until now, those valves were fixed in size and often made from animal tissue, which degrades over time—meaning multiple high-risk operations throughout childhood.
The Autus valve changes that. Approved by the FDA in May 2024 after rigorous review, it’s the first heart valve designed to expand inside the body. Using a small balloon threaded through a blood vessel—a common, low-risk procedure—doctors can widen the valve as the child grows, avoiding major surgery. Its leaflets are made of a durable synthetic material, a first for any FDA-approved heart valve, which may also last longer than animal-based ones.
In a study of 62 children across 12 hospitals, every implantation was successful. There were no deaths, strokes, or clots requiring treatment. Two children who started to outgrow their valves had them expanded non-surgically, proving the concept works in real patients. Dr. Emile Bacha, surgeon-in-chief at NewYork-Presbyterian/Columbia University Irving Medical Center and a trial investigator, called it exactly what families have waited for: a valve that grows with the child.
This isn’t just convenience—it’s transformation. Fewer surgeries mean less pain, lower infection risk, and more normal childhoods. The FDA’s Breakthrough Device designation helped speed up approval, recognizing the urgent need. While long-term data is still being collected, early results offer real hope.
For kids like Mateo, this valve isn’t just medical technology—it’s freedom to run, play, and grow without counting down the years to their next operation.